PRODUCT NEWS

These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

Sep. 03, 2009 Merck Launches SAFLUTAN® (tafluprost) in International Markets
May 19, 2009 Merck to Launch TREDAPTIVE™ (ER niacin/laropiprant) in International Markets Later This Year
FOSAMAX® (ALENDRONATE SODIUM TABLETS)
Jul. 29, 2009   Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw
     
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
Patient Product Information
Oct. 21, 2009   CDC Advisory Committee on Immunization Practices Votes for Permissive Use and for Vaccines for Children Funding for GARDASIL® for Boys and Young Men
Oct. 16, 2009   FDA Approves GARDASIL® for Use in Boys and Young Men
Sep. 09, 2009   FDA Advisory Committee Recommends Approval for Use of GARDASIL® in Boys and Men
Aug. 20, 2009   Merck is Pleased the FDA and CDC Re-affirm the Safety Profile of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant]
Aug. 18, 2009   New Study Reinforces Safety Profile of GARDASIL®, the Cervical Cancer Vaccine
Jan. 09, 2009   GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification
     
ISENTRESS™ (raltegravir)
Patient Product Information
Sep. 13, 2009   Merck's ISENTRESS® (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients
Jul. 31, 2009   FDA Approves Expanded Use of ISENTRESS® (raltegravir) in Combination Therapy for Adult Patients with HIV-1 Infection to Include Patients Not Previously Treated with HIV Medicines
Jul. 20, 2009   ISENTRESS® (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
     
JANUMET™(sitagliptin/metformin HCl) tablets
Patient Product Information
Sep. 25, 2009   Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin
Jun. 08, 2009   Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
Jun. 06, 2009   In Investigational Studies, New Uses of JANUVIATM(sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes
     
JANUVIA™ (sitagliptin)
Patient Product Information
Sep. 25, 2009   Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union
Jun. 08, 2009   Initial Therapy with Janumet™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
Jun. 06, 2009   Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin
Nov. 21 2008   New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
     
SINGULAIR® (montelukast)
Patient Product Information
Aug. 19, 2009   Merck Wins SINGULAIR® Patent Infringement Lawsuit
Jun. 12, 2009   Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
May 29, 2009   Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent
Jan. 13, 2009   Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast)
Mar. 27, 2008   Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™)